Inogen Inc (NASDAQ:INGN)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $62.18 and last traded at $62.75, with a volume of 2570 shares. The stock had previously closed at $63.70.

A number of equities research analysts have commented on INGN shares. BidaskClub cut shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, June 27th. JPMorgan Chase & Co. raised their price target on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an “overweight” rating in a report on Wednesday, July 3rd. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from $11.00 to $17.00 in a report on Wednesday, May 8th. Finally, Needham & Company LLC upgraded shares of Smart Global from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Inogen currently has a consensus rating of “Hold” and an average target price of $117.60.

The firm has a market cap of $1.36 billion, a PE ratio of 27.03, a price-to-earnings-growth ratio of 2.60 and a beta of 1.45. The company’s fifty day moving average price is $66.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.35 and a quick ratio of 6.70.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.05). The business had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. The firm’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.48 earnings per share. On average, sell-side analysts anticipate that Inogen Inc will post 1.63 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in shares of Inogen by 30.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,113 shares of the medical technology company’s stock worth $138,000 after acquiring an additional 258 shares during the last quarter. BlackRock Inc. increased its stake in Inogen by 4.4% in the fourth quarter. BlackRock Inc. now owns 2,233,303 shares of the medical technology company’s stock valued at $277,307,000 after purchasing an additional 93,873 shares during the last quarter. Texas Permanent School Fund increased its stake in Inogen by 4.8% in the fourth quarter. Texas Permanent School Fund now owns 11,549 shares of the medical technology company’s stock valued at $1,434,000 after purchasing an additional 534 shares during the last quarter. Advisor Group Inc. increased its stake in Inogen by 210.0% in the fourth quarter. Advisor Group Inc. now owns 992 shares of the medical technology company’s stock valued at $123,000 after purchasing an additional 672 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Inogen by 18.6% in the fourth quarter. Northern Trust Corp now owns 293,842 shares of the medical technology company’s stock valued at $36,487,000 after purchasing an additional 46,036 shares during the last quarter. Hedge funds and other institutional investors own 98.61% of the company’s stock.

Inogen Company Profile (NASDAQ:INGN)

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.